Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Top Page
Amarin
(NASDAQ:AMRN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$16.00
▲(10.27% Upside)
Action:ReiteratedDate:03/03/26
The score is held down primarily by weak financial performance (shrinking revenue, ongoing losses, and inconsistent/weak cash flow) and bearish technicals (below key moving averages with negative MACD). The latest earnings call provides partial support via cost-cutting progress, positive operating cash flow in 2025, strong liquidity/no debt, and partnership upside, but revenue pressure and variability keep overall risk elevated.
Positive Factors
Strong liquidity and low leverage
Amarin's ample cash, no debt and sizable working capital provide multi-quarter runway to fund operations, complete restructuring, support regulatory filings and partner launches. This reduces near-term insolvency risk and gives management optionality to execute long-term commercialization plans.
Negative Factors
Multi-year revenue decline
A sustained drop in sales over several years reflects structural demand erosion and reduced scale for the core product. Persistent revenue contraction weakens pricing leverage, reduces R&D and commercial flexibility, and makes it harder to offset rising competition despite cost cuts.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and low leverage
Amarin's ample cash, no debt and sizable working capital provide multi-quarter runway to fund operations, complete restructuring, support regulatory filings and partner launches. This reduces near-term insolvency risk and gives management optionality to execute long-term commercialization plans.
Read all positive factors
Amarin (AMRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$301.96M
Dividend YieldN/A
Average Volume (3M)57.96K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-6.31%
EPS Growth-115.62%
CountryUS
Employees275
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding20,803,957
10 Day Avg. Volume34,483
30 Day Avg. Volume57,961
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)12.61
Price to Sales (P/S)31.70
P/FCF Ratio859.05
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.47
Enterprise Value/Ebitda-10.83
Forecast
1Y Price Target
$12.00Price Target Upside-17.30% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$160.19M
Amarin Business Overview & Revenue Model
Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead ...
How the Company Makes Money
Amarin makes money primarily by selling its prescription product icosapent ethyl under the brand names VASCEPA (U.S.) and VAZKEPA (in certain non-U.S. markets). Revenue is generated when wholesalers, pharmacies, hospitals, and other customers purc...
Amarin Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful operational progress: sizable cost reductions, a narrowed operating loss, positive operating cash flow, a strong cash position and a strategic Recordati partnership with immediate $25 million upfront consideration and substantial milestone potential. These positives were tempered by a notable year-over-year revenue decline (approx. 21% in Q4), a large drop in rest-of-world revenue driven by prior-year stocking orders, ongoing U.S. pricing pressure in a generic environment, and near-term revenue variability as the company transitions to a partnered international model. Management expects full run-rate savings by mid-2026 and reiterated confidence in defending U.S. exclusivity and expanding internationally through partners, making the net tone constructive but cautious.Positive Updates
Significant Operating Expense Reductions
Total operating expenses declined 31% year-over-year in Q4 (a $13.5 million reduction). SG&A fell 46% and represented 41% of total net sales versus 59% in prior-year Q4. Excluding restructuring charges, total OpEx declined 41% year-over-year, reflecting realization of global restructuring savings.
Negative Updates
Q4 Net Revenue Decline
Total net revenue for Q4 2025 was $49.2 million versus $62.3 million in prior-year Q4, a decline of approximately 21.0% year-over-year.
Read all updates
Q4-2025 Updates
Positive
Negative
Significant Operating Expense Reductions
Total operating expenses declined 31% year-over-year in Q4 (a $13.5 million reduction). SG&A fell 46% and represented 41% of total net sales versus 59% in prior-year Q4. Excluding restructuring charges, total OpEx declined 41% year-over-year, reflecting realization of global restructuring savings.
Read all positive updates
Company Guidance
The company guided that it expects to realize the full ~$70 million of annualized operating expense savings from its global restructuring by 6/30/2026 (having realized roughly half as of 12/31/2025), with total restructuring charges to date of $36.2 million and $4.1 million recorded in Q4 and the last charges expected in early 2026; management reiterated an expectation of positive cash flow for full‑year 2026 after generating $7.0 million of operating cash flow in 2025 and finishing the year with $303 million of cash and investments, no debt, and $455 million of working capital. Q4 financials highlighted metrics that inform the guidance: total net revenue of $49.2 million (vs. $62.3 million prior‑year Q4), U.S. sales down 7% (driven by lower net selling price), Europe product revenue of $2.3 million (including $0.9 million in supply shipments), rest‑of‑world revenue of $3.1 million (vs. $11.9 million prior), total operating expenses down 31% ($13.5 million), COGS down 63% (10% ex one‑time items), SG&A down 46% and representing 41% of net sales (vs. 59% prior), and an operating loss narrowed to $2.3 million (from $16.0 million, excluding restructuring). The company also noted that its Recordati partnership delivered $25 million upfront with up to $150 million of potential future milestones (first payable at $100 million Recordati annual net sales), and cautioned that partnered revenues will produce quarter‑to‑quarter variability and that U.S. volume pressure historically occurs primarily in Q1.Amarin Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 182.75M | 228.61M | 306.91M | 369.19M | 583.19M |
| Gross Profit | 120.87M | 81.38M | 165.54M | 242.48M | 461.86M |
| EBITDA | -41.54M | -74.18M | -50.70M | -100.69M | 14.28M |
| Net Income | -38.80M | -82.18M | -59.11M | -105.80M | 7.73M |
Balance Sheet | |||||
| Total Assets | 670.77M | 685.35M | 831.68M | 886.18M | 1.07B |
| Cash, Cash Equivalents and Short-Term Investments | 302.79M | 294.22M | 320.66M | 309.36M | 454.13M |
| Total Debt | 12.16M | 7.72M | 8.74M | 10.02M | 8.58M |
| Total Liabilities | 211.49M | 199.17M | 279.59M | 290.85M | 400.97M |
| Stockholders Equity | 459.28M | 486.18M | 552.10M | 595.33M | 667.10M |
Cash Flow | |||||
| Free Cash Flow | 6.74M | -31.02M | 6.88M | -179.98M | -66.53M |
| Operating Cash Flow | 6.74M | -31.03M | 6.91M | -179.98M | -66.53M |
| Investing Cash Flow | 8.85M | -45.98M | -25.62M | 175.18M | 104.09M |
| Financing Cash Flow | -2.04M | -1.44M | 230.89K | -378.77K | -5.07M |
Amarin Technical Analysis
Negative
14.51
Price Trends
14.84
Negative
14.95
Negative
15.64
Negative
Market Momentum
-0.09
Negative
46.31
Neutral
64.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Negative. The current price of 14.51 is below the 20-day moving average (MA) of 14.69, below the 50-day MA of 14.84, and below the 200-day MA of 15.64, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 64.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMRN.
Amarin Risk Analysis
Amarin disclosed 65 risk factors in its most recent earnings report. Amarin reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amarin Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $553.64M | 0.72 | 240.83% | ― | 79.13% | 2798.12% | |
55 Neutral | $1.27B | -39.78 | -23.29% | ― | ― | 79.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $397.21M | -2.29 | -65.76% | ― | ― | 18.39% | |
49 Neutral | $420.13M | -3.61 | -49.35% | ― | -61.54% | 31.25% | |
48 Neutral | $301.96M | -149.32 | -8.36% | ― | -6.31% | -115.62% | |
41 Neutral | $108.33M | -9.19 | -63.75% | ― | ― | 4.23% |
* Healthcare Sector Average
AMRN
Amarin
14.55
4.74
48.32%
ALT
Altimmune
3.29
-1.24
-27.37%
RIGL
Rigel
31.39
14.35
84.21%
ALDX
Aldeyra Therapeutics
1.79
-0.41
-18.64%
RCKT
Rocket Pharmaceuticals
3.64
-2.89
-44.26%
CRVS
Corvus Pharmaceuticals
15.25
12.01
370.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.